MIRCERA.com

MIRCERA is a continuous erythropoietin receptor activator with a different receptor-binding activity to other erythropoiesis-stimulating agents (ESAs). The reduced affinity of MIRCERA for the erythropoietin receptor allows continuous stimulation which achieves stable haemoglobin levels in the target range.¹

 

MIRCERA has the longest half-life of all ESAs; six times longer than darbepoetin alfa intravenous (IV) and 27 times longer than epoetin alfa IV (see Figure).^2–6 This extended half-life allows more frequent activation of erythropoietin receptor compared with epoetin.⁷

 

 

 Half-life of erythropoiesis-stimulating agents.^2–6

 

References:

 

1. Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly C.E.R.A. maintains stable haemoglobin control in patients with chronic kidney disease on dialysis and convert dircetly from epoetin one to three times weekly. Clin J Amer Soc Nephrol. 2007 doi:10.2215/CJN.03631006.
2. Aranesp® Summary of Product Characteristics. Amgen. 2006.
3. MIRCERA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.
4. Eprex® Summary of Product Characteristics. Janssen-Cilag Ltd. 2006.
5. NeoRecormon® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.
6. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006 doi:10.2215/CJN.00730306.
7. Haselbeck A, Reigner B, Jordan P, et al. Pre-clinical and phase I pharmacokinetic and mode-of-action studies of C.E.R.A. (Continuous Erythropoietin Receptor Activator), a novel erythropoietic agent with an extended serum half-life. Proc Am Soc Clin Oncol. 2003;22:748 (abstract 3006).